Allogene Therapeutics, Inc. Cash Flow Statement

Cash Flow Statement Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -211.50M-184.59M-250.22M-257.00M-330.97M-327.26M-257.59M
Depreciation and Depletion 1.05M4.42M7.43M10.45M14.29M14.20M
Share-based Compensation 18.57M46.06M65.26M80.82M83.60M65.95M51.74M
Deferred Taxes 41.92M
Gains from Investment Securities 33.02M13.83M-0.03M20.08M31.36M7.00M-4.28M
Asset Writedowns and Impairment 13.24M15.72M
Cash from Operations -44.65M-137.35M-115.09M-184.81M-220.52M-237.73M-200.30M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 1.04M3.60M-3.25M-6.96M-2.89M6.81M8.35M
Amortization of Deferred Charges 3.36M
Depreciation & Amortization (CF) 1.05M4.42M7.43M10.45M14.29M14.20M13.64M
Change in Working Capital
Change in Account Payables 8.80M-0.98M0.61M-0.77M4.87M-7.50M-0.50M
Change in Accured Expenses 12.14M6.35M18.73M3.65M1.75M-6.82M-1.26M
Investing Activities
Capital Expenditures 3.23M50.79M65.96M21.45M5.19M1.52M0.69M
Change in Acquisitions & Divestments 19.23M472.58M593.63M728.39M359.46M597.81M432.46M
Cash from Investing Activities -632.80M164.08M-505.12M163.66M106.16M163.29M75.69M
Financing Activities
Other financing activities 2.28M
Debt Issuance and Repayment
Long-Term Debt Issuances 116.84M
Change in Capital Stock
Shares Issued 343.69M2.96M595.73M8.35M2.46M2.50M1.53M
Preferred Shares Issued 299.28M
Misc.
Cash from Financing Activities 771.18M58.96M633.59M11.96M2.95M95.69M116.67M
Change in Cash 93.73M85.69M13.38M-9.19M-111.41M21.25M-7.94M
Free Cash Flow -47.89M-188.14M-181.05M-206.26M-225.71M-239.25M-200.99M
Net Cash Flow 93.73M85.69M13.38M-9.19M-111.41M21.25M-7.94M